<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CC7FDF4-8B09-4C9F-8291-B964EA78CF79"><gtr:id>2CC7FDF4-8B09-4C9F-8291-B964EA78CF79</gtr:id><gtr:name>Lonza Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECE55F4B-683C-4E67-B584-4B8536B9587D"><gtr:id>ECE55F4B-683C-4E67-B584-4B8536B9587D</gtr:id><gtr:name>PALL Europe</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CC7FDF4-8B09-4C9F-8291-B964EA78CF79"><gtr:id>2CC7FDF4-8B09-4C9F-8291-B964EA78CF79</gtr:id><gtr:name>Lonza Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECE55F4B-683C-4E67-B584-4B8536B9587D"><gtr:id>ECE55F4B-683C-4E67-B584-4B8536B9587D</gtr:id><gtr:name>PALL Europe</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/71621288-4430-4119-B31A-5630A76616A6"><gtr:id>71621288-4430-4119-B31A-5630A76616A6</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Carden</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9511462-1605-4095-BC4C-F24797BF2FD9"><gtr:id>C9511462-1605-4095-BC4C-F24797BF2FD9</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Smales</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A1A1040E-575B-4D63-848C-12CB5EC47B68"><gtr:id>A1A1040E-575B-4D63-848C-12CB5EC47B68</gtr:id><gtr:firstName>Mick</gtr:firstName><gtr:surname>Tuite</gtr:surname><gtr:orcidId>0000-0002-5214-540X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/344D3F49-5E93-4D3D-AA4F-A7BD7BB1C676"><gtr:id>344D3F49-5E93-4D3D-AA4F-A7BD7BB1C676</gtr:id><gtr:firstName>Tobias</gtr:firstName><gtr:surname>von der Haar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6316086C-0FDE-4D4C-9C77-29E04BAFE7CE"><gtr:id>6316086C-0FDE-4D4C-9C77-29E04BAFE7CE</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Klappa</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE005969%2F1"><gtr:id>70CA2988-CB75-4C82-BAA5-8441E3CE5F5B</gtr:id><gtr:title>Characterization of post-transcriptional constraints that determine rP yield during bioprocessing in mammalian cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E005969/1</gtr:grantReference><gtr:abstractText>We all have an in-built defence mechanism to respond to infection when our body recognises a foreign 'invader'. A type of cell known as a B cell responds to infection by changing into an antibody-producing cell. Antibodies are proteins that work by attacking the foreign invader and destroying it, clearing infection by removing the foreign agent. Because antibodies are our body's natural defence against disease, many new antibody type drugs are being developed to help treat a number of human diseases such as cancer. These antibodies are usually produced by cells kept in a culturing solution under defined conditions. The problem is that these antibodies must be in a special shape; otherwise they do not work. The cells used to produce such antibodies have a very complex set of machinery to make the antibodies and put their components together into the right shape. This works very well when the cell is not expected to make much of the antibody in question. However, the cells we use to make antibodies are much less efficient at producing these drugs when we try and produce more of the product. As a result, we are not able to produce enough of these drugs and the cost and demand for them is therefore high e.g. the breast cancer drug Herceptin. The root of the problem is that when cells are asked to produce much more protein to meet our needs the machinery can no longer cope / the cells sometimes die or else don't produce antibodies of the right shape, of no clinical use whatsoever. It is largely agreed that this problem will become even serious as further antibody-based drugs are developed. The research proposed here will investigate how the cell machinery for making proteins works and examine whether, and in what ways, it can be manipulated to produce more antibody. We want to determine the different parts of this machinery that are limiting in terms of making the antibody, and then investigate how these parts work together to ultimately produce the antibody of interest. At present it is unknown if this is possible, and the process is poorly understood in the mammalian cells presently used to produce antibodies. We will employ a combination of new state-of-the-art technologies and approaches to take apart the antibody assembly line in mammalian cells in a step-wise manner, and then using the information gathered will determine the relationship between each step of the assembly process. Ultimately this should enable the manipulation of cells to change the balance of each step in the assembly line to produce more of the target antibody drug at reduced cost and higher quality. As stated above, this is extremely important as it is expected that with an increasing number of protein 'drugs' being developed we will lack the capability of producing large enough amounts to meet the required demand for these new drugs for the majority, as opposed to for those who can afford what must currently remain prohibitively expensive, but very effective, medicines.</gtr:abstractText><gtr:technicalSummary>In recent years the capacity of expression systems (e.g. E. coli, animal cells) to produce recombinant proteins (rP) has advanced through improved growth medium, vector systems and bioprocessing. On-the-other-hand, our understandings of those cellular processes that constrain or limit rP production (rPP) during bioprocessing are poorly understood and open to conjecture. The proposed programme of research will utilise a combination of related approaches to investigate the hypothesis that it is the balance between mRNA levels and their regulatory features, mRNA turnover, the translational machinery, key chaperones, protein folding/degradation, and the cell's ability to coordinate and manipulate each of these processes to the demands of heterologous protein production that ultimately determines recombinant protein expression levels. To achieve this 5 related approaches will be employed. The 1st approach will characterise the diversity of translational machinery within cell populations and the effect of 5'-UTRs on mRNA translation. The 2nd approach will investigate those translational/post-translational mechanisms that limit the quantity and quality of rPP, determining the flux throughout the system by measurement of cell division rates, mRNA and protein levels and half-lives in model expression systems. The 3rd is targeted at the functional and physical link between translation and the chaperone CCT. The 4th approach will investigate the coordination and functional relationship between key members of the chaperone network, protein folding/turnover, and the relationship of these events to rPP. The 5th approach is to investigate disulphide bond formation pathways during protein folding. The proposal provides a rational approach towards understand the limitations and processes/molecular response(s) governing rPP in eukaryotic systems (outcome 1) and for identification of rational targets/strategies for enhancing rPP and for novel gene expression technologies (outcome 2).</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>987761</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lonza Group</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Lonza Biologics Mass Spec Fingerprinting Project</gtr:description><gtr:id>F2CCFD43-65E4-42A7-B7C9-802CE20EC031</gtr:id><gtr:impact>IP/Patents, publications.</gtr:impact><gtr:outcomeId>545dd8f08c9c61.66270905-1</gtr:outcomeId><gtr:partnerContribution>Cell line development, fermentation and bioreactor runs and validation, provision of reagents and expertise.</gtr:partnerContribution><gtr:piContribution>Development of a mass spectrometry fingerprinting technology for the identification of highly productive recombinant CHO cell lines.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PALL Europe</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pall Case Studentship</gtr:description><gtr:id>CF926691-6327-4975-A48B-00327BAAB435</gtr:id><gtr:impact>PhD thesis, publications.</gtr:impact><gtr:outcomeId>545cf117a533b7.90197007-1</gtr:outcomeId><gtr:partnerContribution>Access to industrial relevant cell lines, culture facilities and materials, consumables. knowhow and knowledge.</gtr:partnerContribution><gtr:piContribution>A PhD CASE Studentship to investigate host cell proteins during bioprocessing including upstream and downstream bioprocesses.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Days At University</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5F41AD14-9375-439F-BB81-663A019A51E7</gtr:id><gtr:impact>This activity is take take parents and secondary students around my research laboratories to explain the research undertaken and to demonstrate some of the research that we do in the laboratory.

Parents and students asked about engineering of cell lines and therapeutic recombinant protein drugs and how these are made, cost implications and on-going research.</gtr:impact><gtr:outcomeId>545cf2a81ff603.43989030</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation on Biosimilar protein based biotherapeutic drugs</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B9B9C46C-60BC-418F-8A6E-5E0B1BA18F19</gtr:id><gtr:impact>The talk stimulated discussion with the nurses and health care professionals present about what biosimilars are and when/how to assess if these are appropriate to administer as opposed to the innovator drug.

Nurses and healthcare professionals asked for further information on biosimilars.</gtr:impact><gtr:outcomeId>545cf4495e9bc0.61133416</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Turkey Public Biotechnology Talk</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C736C0F4-293A-45C3-8BA7-5FACF1167572</gtr:id><gtr:impact>Presentation to public audience in Turkey on behalf of the British Council around biotechnology and its application. Event was filmed and followed by a question and answer session, answering questions sent in before the talk by social media and then from the audience. The event was filmed and shown on national TV in Turkey. Large range of topics discussed around the application of biotechnology to every day life and issues with long discussion/debate.</gtr:impact><gtr:outcomeId>56dcb0d7035570.23392440</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.britishcouncil.org.tr/en/programmes/education/science-innovation-talks/biotechnology</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>86657</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Early Career Develoment Award</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>The Leverhulme Trust</gtr:fundingOrg><gtr:fundingRef>ECF-2001-339</gtr:fundingRef><gtr:id>B60626F6-553D-4CFE-B46F-7E8CB483B756</gtr:id><gtr:outcomeId>58c86a68454417.59486554</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>173850</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Industrial Fellowship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:fundingRef>IF130004</gtr:fundingRef><gtr:id>243C7FF6-ADF7-4275-9DF5-003FB6D8EAFA</gtr:id><gtr:outcomeId>545ddacef3e427.59674107</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings from these studies are being used by the biopharmaceutical industry and those industries that manufacture biopharmaceutical protein based drugs to enhance the predictability of expression of mammalian cell lines and hence develop more efficient cell lines for use commercially. These findings also formed the basis of a further study funded in whole by industry to develop methods to 'fingerprint' mammalian cell lines, resulting in the protection (via patent) of the resulting technology, using MALDI mass spectrometry to rapidly fingerprint and select recombinant cell lines for commercial use.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>CB4097C4-311F-4B65-9B99-7E2E0C21DBF5</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>545ba82c8e4fe4.86719090</gtr:outcomeId><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Development of mass spectrometry method to identify highly productive recombinant mammalian cell lines. Ideal came from original BBSRC work and then funded development via industry.</gtr:description><gtr:grantRef>BB/E005969/1</gtr:grantRef><gtr:id>8B030518-D76F-4D3E-9B47-CCFF09C726B5</gtr:id><gtr:impact>Invitation to talks.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56dcb34b6cccf6.74189753</gtr:outcomeId><gtr:patentId>EP 2447717 B1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Rapid method for targeted cell (line) selection</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>i. Development of mathematical models using experimental data that describe the gene expression pathway for luciferase and an industrially relevant IgG (monoclonal antibody such as those used for the treatment of disease in the clinic) from mammalian expression systems confirming limitations are cell line specific, however translational limitations for the IgG heavy chain results in non-productive light chain/light chain dimmers being secreted in some high producers. These models have identified targets for cell engineering or can be used for screening.

ii. Demonstrating a direct link between the translational machinery and specific chaperones that influence protein synthesis/cell growth and identification of targets for cell engineering/screening strategies. Further, that manipulation of untranslated regions (UTRs) influences recombinant protein synthesis towards the end of culture and may allow for enhanced yields.

iii. An orchestrated panel of chaperones controls folding of recombinant proteins and yeast chaperone over-expression in mammalian cells can aid recombinant protein expression and disaggregation. Screening for the appropriate balance of chaperones in host cells is preferable to manipulation.</gtr:description><gtr:exploitationPathways>These findings could be utilised and implementation of our strategies developed through the knowledge generated during this programme of work to further improve biotherapeutic recombinant protein (protein based drugs for use in the clinic for the treatment of disease) expression from mammalian cell lines either through cell engineering strategies or the use of novel screening approaches to select either host or recombinant cell lines with enhanced bioprocessing properties (enhanced yields or biomass).</gtr:exploitationPathways><gtr:id>8E200095-AE70-4702-961F-237590C66470</gtr:id><gtr:outcomeId>545ba71bf40941.32978512</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4A046934-90B8-4E3D-9A56-87FB80D03E3E</gtr:id><gtr:title>Comprehensive Biotechnology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85214329544e182740996e9f0c73aa06"><gtr:id>85214329544e182740996e9f0c73aa06</gtr:id><gtr:otherNames>Mead E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>9780080885049</gtr:isbn><gtr:outcomeId>545e760c3e4826.37858205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB735F2E-FC02-4CF3-B068-CAB437FDE67D</gtr:id><gtr:title>Engineering the chaperone network of CHO cells for optimal recombinant protein production and authenticity.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7621335a3fb15f7ca4197d55cbaec573"><gtr:id>7621335a3fb15f7ca4197d55cbaec573</gtr:id><gtr:otherNames>Joss? L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>54501505b767d7.93905297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D0BB082-FF8D-4BD4-A6BB-3CCC8A5CD221</gtr:id><gtr:title>Protein disulfide isomerase does not control recombinant IgG4 productivity in mammalian cell lines.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3802f4f03c57f57cc2854c31fb0dda74"><gtr:id>3802f4f03c57f57cc2854c31fb0dda74</gtr:id><gtr:otherNames>Hayes NV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5450159c494196.89833700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E48707A-BA54-4EA7-9001-DA605F4F79E7</gtr:id><gtr:title>Identification of the limitations on recombinant gene expression in CHO cell lines with varying luciferase production rates.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27b59f74c619269c76eb1de2f255e0e"><gtr:id>d27b59f74c619269c76eb1de2f255e0e</gtr:id><gtr:otherNames>Mead EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5450161a25c246.52602454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDE1CDE7-87EC-49DD-B5E2-FE4E96E3E90D</gtr:id><gtr:title>Human TorsinA can function in the yeast cytosol as a molecular chaperone.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95a76a051d957449717ccd378f50abd3"><gtr:id>95a76a051d957449717ccd378f50abd3</gtr:id><gtr:otherNames>Adam I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>5a350fca4aac38.60877399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>379F77BB-11AC-4845-B86F-14CD4541032C</gtr:id><gtr:title>Experimental and in silico modelling analyses of the gene expression pathway for recombinant antibody and by-product production in NS0 cell lines.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27b59f74c619269c76eb1de2f255e0e"><gtr:id>d27b59f74c619269c76eb1de2f255e0e</gtr:id><gtr:otherNames>Mead EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54501482f00390.27585783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30ED2294-EF82-4CCF-9023-045E1B8281FE</gtr:id><gtr:title>Modulation of phosducin-like protein 3 (PhLP3) levels promotes cytoskeletal remodelling in a MAPK and RhoA-dependent manner.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3802f4f03c57f57cc2854c31fb0dda74"><gtr:id>3802f4f03c57f57cc2854c31fb0dda74</gtr:id><gtr:otherNames>Hayes NV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545014e61b9d46.34636900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>949391D2-55C5-409E-ACC8-E40D89FC38E0</gtr:id><gtr:title>MALDI-ToF mass spectrometry coupled with multivariate pattern recognition analysis for the rapid biomarker profiling of Escherichia coli in different growth phases.</gtr:title><gtr:parentPublicationTitle>Analytical and bioanalytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14605f0b518211d46aa2dc7538d9daa2"><gtr:id>14605f0b518211d46aa2dc7538d9daa2</gtr:id><gtr:otherNames>Momo RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1618-2642</gtr:issn><gtr:outcomeId>54501402df8852.74550895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E484C963-0350-47A8-9990-A5FA9CE8849C</gtr:id><gtr:title>Transient expression of human TorsinA enhances secretion of two functionally distinct proteins in cultured Chinese hamster ovary (CHO) cells.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7621335a3fb15f7ca4197d55cbaec573"><gtr:id>7621335a3fb15f7ca4197d55cbaec573</gtr:id><gtr:otherNames>Joss? L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>545015bc1172e8.84147105</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E005969/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>